COST-EFFECTIVENESS AND BUDGET IMPACT OF CAFFEINE CITRATE VERSUS AMINOPHYLLINE FOR APNEA OF PREMATURITY ACROSS A PUBLIC HEALTHCARE SYSTEM IN MEXICO (ISPOR 2026) - Mar 6, 2026 - Abstract #EE63; Pres time: May 18, 2026; 10:30 AM - 01:30 PM; "This study evaluates the cost-effectiveness and budget impact of Peyona® (caffeine citrate; CC) compared with aminophylline for the treatment of apnea of prematurity from the perspective of the ISSSTE in Mexico. A cost-effectiveness analysis combined with a budget impact analysis was conducted from the institutional perspective of ISSSTE. CC represents a cost-effective and cost-saving alternative to aminophylline for the management of apnea of prematurity within ISSSTE, supporting efficient resource allocation and long-term economic sustainability of neonatal care programs."
Cost effectiveness • HEOR • Prematurity
|
|
José Ángel Paladio-Hernández, MA, MS 1; Angélica Hurtado-Vilchis, BA, MS 2; Raquel Díaz-Rojas, MBA 3; Madai Deolarte, MA 4
|